Application of liposomes in drug development - focus on gastroenterological targets

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1325-1334

  Zhang, Jian Xin ^a   Wang, Kun ^a   Mao, Zheng Fa ^a   Fan, Xin ^a   Jiang, De Li ^b   Chen, Min ^b   Cui, Lei ^a   Sun, Kang ^a   Dang, Sheng Chun ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

Colorectal cancer; Drug delivery; Inflammatory bowel disease; Liposome

Indexed keywords

AMOXICILLIN; CARNITINE; CATALASE; CD40 ANTISENSE OLIGONUCLEOTIDE; CLODRONIC ACID; CURCUMIN; DOCETAXEL; DRUG CARRIER; FLUOROOROTIC ACID; GASTROINTESTINAL AGENT; GENERIC DRUG; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HYBRID LIPOSOME; INTERLEUKIN 10; INTERLEUKIN 4; IRINOTECAN; LIPOSOME; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PEGYLATED LIPOSOME; PHOTOSENSITIZING AGENT; RADIOSENSITIZING AGENT; RANITIDINE BISMUTH CITRATE; SUPEROXIDE DISMUTASE; TEMOPORFIN; TEMPAMINE; THERMOSENSITIVE LIPOSOME; TRANSFERRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTISENSE THERAPY; APOPTOSIS; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; COLITIS; COLON CANCER; COLORECTAL CANCER; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENTERITIS; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HUMAN; INTESTINE INJURY; LIPOSOMAL DELIVERY; LIPOSOMAL GENE DELIVERY SYSTEM; METRONOMIC DRUG ADMINISTRATION; NONHUMAN; PANCREAS CANCER; REVIEW; SENSITIVITY ANALYSIS; STOMACH CANCER; STOMACH CARCINOMA; ULCER; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

COLORECTAL CANCER; DRUG DELIVERY; INFLAMMATORY BOWEL DISEASE; LIPOSOME;

ANIMALS; COLORECTAL NEOPLASMS; DRUG DISCOVERY; HUMANS; INFLAMMATORY BOWEL DISEASES; LIPOSOMES;

EID: 84876048012     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S42153     Document Type: Review

References (122)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526-535.
2. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91(4):854-862.
3. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18): 1228-1233.
4. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006;23(8):1097-1104.
5. Siegmund B, Zeitz M. Innate and adaptive immunity in inflammatory bowel disease. World J Gastroenterol. 2011;17(27):3178-3183.
6. Huang JS, Noack D, Rae J, et al. Chronic granulomatous disease caused by a deficiency in p47(phox) mimicking Crohn's disease. Clin Gastroenterol Hepatol. 2004;2(8):690-695.
7. Schinella RA, Greco MA, Cobert BL, Denmark LW, Cox RP. Hermansky-Pudlak syndrome with granulomatous colitis. Ann Intern Med. 1980;92(1):20-23.
8. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157(3):1261-1270.
9. Meira LB, Bugni JM, Green SL, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest. 2008;118(7):2516-2525.
10. Westbrook AM, Wei B, Braun J, Schiestl RH. Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res. 2009; 69(11):4827-4834.
11. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073-1081.
12. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4): 1079-1099.
13. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007;21(20):2525-2538.
14. Rizzo A, Pallone F, Monteleone G, Fantini MC. Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol. 2011;17(26):3092-3100.
15. Compare D, Nardone G. Contribution of gut microbiota to colonic and extracolonic cancer development. Dig Dis. 2011;29(6):554-561.
16. Mufamadi MS, Pillay V, Choonara YE, et al. A review on composite liposomal technologies for specialized drug delivery. J Drug Deliv. 2011;2011:939851.
17. Kesisoglou F, Zimmermann EM. Novel drug delivery strategies for the treatment of inflammatory bowel disease. Expert Opin Drug Deliv. 2005;2(3):451-463.
18. Qualls JE, Kaplan AM, van Rooijen N, Cohen DA. Suppression of experimental colitis by intestinal mononuclear phagocytes. J Leukoc Biol. 2006;80(4):802-815.
19. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(7): 390-407.
20. Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol. 2008;14(3):390-400.
21. Yadav PK, Liu Z. Current strategies for the treatment of ulcerative colitis. Recent Pat Inflamm Allergy Drug Discov. 2009;3(1): 65-72.
22. Polese L, Angriman I, Scarpa M, et al. Role of CD40 and B7 costimulators in inflammatory bowel diseases. Acta Biomed. 2003; 74 Suppl 2:65-70.
23. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. T{stroke}hromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6(2):114.
24. Yamada A, Sayegh MH. The CD154-CD40 costimulatory pathway in transplantation. Transplantation. 2002;73(Suppl 1):S36-S39.
25. Sakata K, Sakata A, Kong L, Vela-Roch N, Talal N, Dang H. Monocyte rescue of human T cells from apoptosis is CD40/CD154 dependent. Scand J Immunol. 1999;50(5):479-484.
26. Arranz A, Reinsch C, Papadakis KA, et al. Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J Control Release. 2012;165(3):163-172.
27. Gao D, Wagner AH, Fankhaenel S, et al. CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis. Gut. 2005;54(1):70-77.
28. Rogy MA, Beinhauer BG, Reinisch W, Huang L, Pokieser P. Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. Hum Gene Ther. 2000;11(12): 1731-1741.
29. Tirosh B, Khatib N, Barenholz Y, Nissan A, Rubinstein A. Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. Mol Pharm. 2009;6(4):1083-1091.
30. Harel E, Rubinstein A, Nissan A, et al. Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa. PLoS One. 2011;6(9): e24202.
31. Rozga J. The role of reactive oxygen metabolites in the pathogenesis of ulcerative colitis: a speculative synthesis. Mater Med Pol. 1989;21(4): 263-268.
32. Jubeh TT, Antler S, Haupt S, Barenholz Y, Rubinstein A. Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine. Mol Pharm. 2005;2(1):2-11.
33. Jubeh TT, Nadler-Milbauer M, Barenholz Y, Rubinstein A. Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD. J Drug Target. 2006;14(3):155-163.
34. D'Argenio G, Calvani M, Casamassimi A, et al. Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes induces carnitine depletion that is reversible by carnitine-loaded liposomes. FASEB J. 2006;20(14):2544-2546.
35. Sonnenberg A, Genta RM. Helicobacter pylori is a Risk Factor for Colonic Neoplasms. Am J Gastroenterol. 2013;108(2):208-215.
36. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808-1825.
37. Muthupalani S, Ge Z, Feng Y, et al. Systemic Macrophage Depletion Inhibits Helicobacter bilis-Induced Proinflammatory Cytokine-Mediated Typhlocolitis and Impairs Bacterial Colonization Dynamics in a BALB/c Rag2-/-Mouse Model of Inflammatory Bowel Disease. Infect Immun. 2012;80(12):4388-4397.
38. Zhang JX, Dang SC, Yin K, Jiang DL. Protective effect of clodronatecontaining liposomes on intestinal mucosal injury in rats with severe acute pancreatitis. Hepatobiliary Pancreat Dis Int. 2011;10(5): 544-551.
39. Singh DY, Prasad NK. Double liposomes mediated dual drug targeting for treatment of Helicobacter pylori infections. Pharmazie. 2011; 66(5):368-373.
40. Jain AK, Agarwal A, Agrawal H, Agrawal GP. Double-liposome-based dual-drug delivery system as vectors for effective management of peptic ulcer. J Liposome Res. 2012;22(3):205-214.
41. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
42. Mullauer FB, van Bloois L, Daalhuisen JB, et al. Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity. Anticancer Drugs. 2011;22(3): 223-233.
43. Gabizon A, Amitay Y, Tzemach D, Gorin J, Shmeeda H, Zalipsky S. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. J Control Release. 2012;160(2):245-253.
44. Lin J, Yu Y, Shigdar S, et al. Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal Doxorubicin in a xenograft model of colorectal cancer. PLoS One. 2012;7(11): e49277.
45. Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori. 2003;89(3):237-249.
46. Rahman S, Cao S, Steadman KJ, Wei M, Parekh HS. Native and beta-cyclodextrin-enclosed curcumin: entrapment within liposomes and their in vitro cytotoxicity in lung and colon cancer. Drug Deliv. 2012;19(7): 346-353.
47. He B, Wang X, Shi HS, et al. Quercetin Liposome Sensitizes Colon Carcinoma to Thermotherapy and Thermochemotherapy in Mice Models. Integr Cancer Ther. 2012.
48. Riganti C, Voena C, Kopecka J, et al. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm. 2011;8(3):683-700.
49. Kan P, Tsao CW, Wang AJ, Su WC, Liang HF. A liposomal formulation able to incorporate a high content of Paclitaxel and exert promising anticancer effect. J Drug Deliv. 2011;2011:629234.
50. Cheng N, Xia T, Han Y, He QJ, Zhao R, Ma JR. Synergistic antitumor effects of liposomal honokiol combined with cisplatin in colon cancer models. Oncol Lett. 2011;2(5):957-962.
51. Riviere K, Kieler-Ferguson HM, Jerger K, Szoka FC Jr. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan. J Control Release. 2011; 153(3):288-296.
52. Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol. 2006;58(6):759-764.
53. Cascinu S, Galizia E, Labianca R, et al. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemother Pharmacol. 2011;68(1):37-43.
54. Ueoka R, Moss R, Swarup S. Extraordinary micellar enantioselectivity coupled to altered aggregate structure. J Am Chem Soc. 1985; 107(7):2185-2186.
55. Komizu Y, Matsumoto Y, Ueoka R. Membrane targeted chemotherapy with hybrid liposomes for colon tumor cells leading to apoptosis. Bioorg Med Chem Lett. 2006;16(23):6131-6134.
56. Hino M, Ichihara H, Matsumoto Y, Ueoka R. Anti-tumor Effects of Cationic Hybrid Liposomes against Colon Carcinoma along with Apoptosis in Vitro. Biol Pharm Bull. 2012;35(11):2097-2101.
57. Komizu Y, Ueoka H, Goto K, Ueoka R. Remarkable inhibitory effects of hybrid liposomes on growth of human colon cancer cells through induction of cell cycle arrest along with apoptosis. Int J Nanomedicine. 2011;6:1913-1920.
58. Ichihara H, Hino M, Umebayashi M, Matsumoto Y, Ueoka R. Intravenous injection of hybrid liposomes suppresses the liver metastases in xenograft mouse models of colorectal cancer in vivo. Eur J Med Chem. 2012;57:143-148.
59. Ichihara H, Funamoto K, Matsushita T, Matsumoto Y, Ueoka R. Histological bioanalysis for therapeutic effects of hybrid liposomes on the hepatic metastasis of colon carcinoma in vivo. Int J Pharm. 2010;394(1-2):174-178.
60. Ichihara H, Zako K, Komizu Y, Goto K, Ueoka R. Therapeutic effects of hybrid liposomes composed of phosphatidylcholine and docosahexaenoic acid on the hepatic metastasis of colon carcinoma along with apoptosis in vivo. Biol Pharm Bull. 2011;34(6):901-905.
61. Rangger C, Helbok A, von Guggenberg E, et al. Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles. Int J Nanomedicine. 2012;7:5889-5900.
62. Yoshizawa Y, Kono Y, Ogawara K, Kimura T, Higaki K. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm. 2011;412(1-2):132-141.
63. Yu NY, Conway C, Pena RL, Chen JY. STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models. Anticancer Res. 2007;27(4B):2541-2545.
64. Kopecka J, Campia I, Olivero P, et al. A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. J Control Release. 2011;149(2):196-205.
65. Yang C, Liu HZ, Fu ZX. PEG-liposomal oxaliplatin induces apoptosis in human colorectal cancer cells via Fas/FasL and caspase-8. Cell Biol Int. 2012;36(3):289-296.
66. Yang C, Liu HZ, Fu ZX. Effects of PEG-liposomal oxaliplatin on apoptosis, and expression of Cyclin A and Cyclin D1 in colorectal cancer cells. Oncol Rep. 2012;28(3):1006-1012.
67. Yang C, Liu HZ, Lu WD, Fu ZX. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma. Oncol Rep. 2011;25(6):1621-1628.
68. Doi Y, Okada T, Matsumoto H, Ichihara M, Ishida T, Kiwada H. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model. Cancer Sci. 2010;101(11): 2470-2475.
69. Maruyama K, Unezaki S, Takahashi N, Iwatsuru M. Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia. Biochim Biophys Acta. 1993;1149(2): 209-216.
70. Unezaki S, Maruyama K, Takahashi N, et al. Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Pharm Res. 1994;11(8):1180-1185.
71. Wells J, Sen A, Hui SW. Localized delivery to CT-26 tumors in mice using thermosensitive liposomes. Int J Pharm. 2003;261(1-2):105-114.
72. Kono K, Nakashima S, Kokuryo D, et al. Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy. Biomaterials. 2011;32(5):1387-1395.
73. Karanth H, Murthy RS. pH-sensitive liposomes - principle and application in cancer therapy. J Pharm Pharmacol. 2007;59(4):469-483.
74. Hong MS, Lim SJ, Oh YK, Kim CK. pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system. J Pharm Pharmacol. 2002;54(1):51-58.
75. Hiraka K, Kanehisa M, Tamai M, et al. Preparation of pH-sensitive liposomes retaining SOD mimic and their anticancer effect. Colloids Surf B Biointerfaces. 2008;67(1):54-58.
76. Banerjee S, Sen K, Pal TK, Guha SK. Poly(styrene-co-maleic acid)-based pH-sensitive liposomes mediate cytosolic delivery of drugs for enhanced cancer chemotherapy. Int J Pharm. 2012;436(1-2):786-797.
77. Shi G, Guo W, Stephenson SM, Lee RJ. Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J Control Release. 2002;80(1-3):309-319.
78. Garg A, Kokkoli E. pH-Sensitive PEGylated liposomes functionalized with a fibronectin-mimetic peptide show enhanced intracellular delivery to colon cancer cell. Curr Pharm Biotechnol. 2011;12(8): 1135-1143.
79. Yoshida M, Watanabe Y, Sato M, et al. Feasibility of chemohyperthermia with docetaxel-embedded magnetoliposomes as minimally invasive local treatment for cancer. Int J Cancer. 2010;126(8):1955-1965.
80. Schroeder A, Honen R, Turjeman K, Gabizon A, Kost J, Barenholz Y. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release. 2009;137(1):63-68.
81. Fayter D, Corbett M, Heirs M, Fox D, Eastwood A. A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technol Assess. 2010;14(37):1-288.
82. Semelakova M, Mikes J, Jendzelovsky R, Fedorocko P. The pro-apoptotic and anti-invasive effects of hypericin-mediated photodynamic therapy are enhanced by hyperforin or aristoforin in HT-29 colon adenocarcinoma cells. J Photochem Photobiol B. 2012;117: 115-125.
83. He Y, Ge H, Li S. Haematoporphyrin based photodynamic therapy combined with hyperthermia provided effective therapeutic vaccine effect against colon cancer growth in mice. Int J Med Sci. 2012;9(8): 627-633.
84. Johnson RP, Chung CW, Jeong YI, Kang DH, Suh H, Kim I. Poly(L-histidine)-tagged 5-aminolevulinic acid prodrugs: new photosensitizing precursors of protoporphyrin IX for photodynamic colon cancer therapy. Int J Nanomedicine. 2012;7:2497-2512.
85. Bombelli C, Caracciolo G, Di Profio P, et al. Inclusion of a photosensitizer in liposomes formed by DMPC/gemini surfactant: correlation between physicochemical and biological features of the complexes. J Med Chem. 2005;48(15):4882-4891.
86. Svensson J, Johansson A, Grafe S, et al. Tumor selectivity at short times following systemic administration of a liposomal temoporfin formulation in a murine tumor model. Photochem Photobiol. 2007;83(5): 1211-1219.
87. Guelluy PH, Fontaine-Aupart MP, Grammenos A, Lecart S, Piette J, Hoebeke M. Optimizing photodynamic therapy by liposomal formulation of the photosensitizer pyropheophorbide-a methyl ester: in vitro and ex vivo comparative biophysical investigations in a colon carcinoma cell line. Photochem Photobiol Sci. 2010;9(9):1252-1260.
88. Gariboldi MB, Ravizza R, Baranyai P, et al. Photodynamic effects of novel 5,15-diaryl-tetrapyrrole derivatives on human colon carcinoma cells. Bioorg Med Chem. 2009;17(5):2009-2016.
89. Wu C, Ma G, Li J, et al. In vivo cell tracking via (18)F-fluorodeoxyglucose labeling: a review of the preclinical and clinical applications in cell-based diagnosis and therapy. Clin Imaging. 2013;37(1):28-36.
90. Kim SH, Won KS, Hwang I, Choi BW, Jo I, Zeon SK. Simultaneous Splenic and Colonic Metastases From Gastric Cancer: Different FDG Avidities According to the Density of Cancer Cells Imaged on FDG PET/CT. Clin Nucl Med. 2013;38(1):60-62.
91. Yasuda S, Kamata H, Machida T, et al. A case of isolated paraaortic lymph node recurrence from colon cancer successfully treated with chemoradiotherapy. Tokai J Exp Clin Med. 2012;37(2):47-50.
92. Chow TH, Lin YY, Hwang JJ, et al. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model. Anticancer Res. 2009;29(6):2111-2120.
93. Chow TH, Lin YY, Hwang JJ, et al. Diagnostic and therapeutic evaluation of 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nucl Med Biol. 2008;35(5):623-634.
94. Chow TH, Lin YY, Hwang JJ, et al. Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. J Nucl Med. 2009;50(12):2073-2081.
95. Lin YY, Li JJ, Chang CH, et al. Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model. Cancer Biother Radiopharm. 2009;24(4):453-460.
96. Tsai CC, Chang CH, Chen LC, et al. Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. Int J Nanomedicine. 2011;6:2607-2619.
97. Hsu CW, Chang YJ, Chang CH, et al. Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts. Cancer Biother Radiopharm. 2012;27(8):481-489.
98. Chang YJ, Chang CH, Yu CY, et al. Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model. Nucl Med Biol. 2010;37(1):95-104.
99. Chen LC, Chang CH, Yu CY, et al. Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice model. Nucl Med Biol. 2008;35(8):883-893.
100. Lin YY, Chang CH, Li JJ, et al. Pharmacokinetics and dosimetry of (111)In/(188)Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models. Cancer Biother Radiopharm. 2011; 26(3):373-380.
101. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol. 2010;197:3-53.
102. Daniels TR, Bernabeu E, Rodriguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820(3):291-317.
103. Ishida O, Maruyama K, Tanahashi H, et al. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res. 2001;18(7):1042-1048.
104. Iinuma H, Maruyama K, Okinaga K, et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer. 2002;99(1):130-137.
105. Maruyama K, Ishida O, Kasaoka S, et al. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). J Control Release. 2004;98(2):195-207.
106. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004;90(3):561-565.
107. Dupouy S, Mourra N, Doan VK, Gompel A, Alifano M, Forgez P. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie. 2011;93(9):1369-1378.
108. Valerie NC, Casarez EV, Dasilva JO, et al. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation. Cancer Res. 2011;71(21):6817-6826.
109. Falciani C, Accardo A, Brunetti J, et al. Target-selective drug delivery through liposomes labeled with oligobranched neurotensin peptides. Chem Med Chem. 2011;6(4):678-685.
110. Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637-650.
111. Ochs AM, Wong L, Kakani V, et al. Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer. 2004;4(4):262-267.
112. Park JW, Kirpotin DB, Hong K, et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001;74(1-3):95-113.
113. Yamamoto Y, Yoshida M, Sato M, et al. Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts. Int J Oncol. 2011;38(1):33-39.
114. Wicki A, Rochlitz C, Orleth A, et al. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res. 2012;18(2): 454-464.
115. Ortiz R, Melguizo C, Prados J, et al. New gene therapy strategies for cancer treatment: a review of recent patents. Recent Pat Anticancer Drug Discov. 2012;7(3):297-312.
116. Wang L, Yao B, Li Q, et al. Gene therapy with recombinant adenovirus encoding endostatin encapsulated in cationic liposome in coxsackievirus and adenovirus receptor-deficient colon carcinoma murine models. Hum Gene Ther. 2011;22(9):1061-1069.
117. Lan KL, Ou-Yang F, Yen SH, Shih HL, Lan KH. Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer. Clin Exp Metastasis. 2010;27(5):307-318.
118. Sun NF, Tian AL, Hua YX, Hu SY, Hu AB. Preparation and characterization of nano-liposome-mediated FL gene in the Lovo cells. Cancer Biother Radiopharm. 2012;27(8):490-494.
119. Sun NF, Meng QY, Tian AL, et al. Nanoliposome-mediated FL/TRAIL double-gene therapy for colon cancer: in vitro and in vivo evaluation. Cancer Lett. 2012;315(1):69-77.
120. Park IK, Kim KK, Cho SH, et al. Intratumoral administration of anti-KITENIN shRNA-loaded PEI-alt-PEG nanoparticles suppressed colon carcinoma established subcutaneously in mice. J Nanosci Nanotechnol. 2010;10(5):3280-3283.
121. Li S, Yu B, An P, et al. Combined liposome-mediated cytosine deaminase gene therapy with radiation in killing rectal cancer cells and xenografts in athymic mice. Clin Cancer Res. 2005;11(9):3574-3578.
122. Kline CL, Shanmugavelandy SS, Kester M, Irby RB. Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biol Ther. 2009;8(19):1831-1837.